港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.914

+1.5570.32%

漲家數：17

跌家數：9

平家數：7

市盈率：- -

高：489.931

開：482.072

低：481.405

收：482.357

成交量：4,000.92萬

成交額：9.12億

市值：3,075.26億

流通市值：2,734.08億

資料載入中...

總覽新聞資訊

「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？

康方生物(09926)出現大手賣出23.3萬股，成交價$96.2，涉資2.241千萬

阿斯达克财经

南新制藥信披違規收處罰，受損股民可索賠

英硅智能（03696）揚升9.32% 機構看好其在AI製藥領域價值持續兑現

港股異動 | 百奧賽圖-B(02315)午後升逾10% 與齊魯製藥簽署全人納米抗體分子非排他授權合作協議

港股異動 | CRO概念股震盪走高企業在手訂單呈「量價齊升」 AI製藥有望重塑醫藥研發業態

港股異動 | 基石藥業-B(02616)午後升逾6% 獲納入港股通標的證券名單國際大行相繼看好公司發展前景

港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%

老虎资讯综合

港股異動 | 雲頂新耀(01952.HK)早盤升逾5% 星必妥PSVT適應症新藥上市申請在華獲批

港股異動 | 雲頂新耀(01952)早盤升逾5% 星必妥PSVT適應症新藥上市申請在華獲批

酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」

中信建投：醫療器械業績持續改善醫療服務收入平穩增長

港股異動 | 禮邦醫藥-B(09637.HK)升逾6% 納入港股通及恒生綜合指數落地美信羅銷售按年增約105% 商業化兑現

港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地美信羅銷售按年增約105% 商業化兑現

大瓜！券商醫藥研究員轉行看電子去了

上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生

每日经济新闻

歸創通橋(02190.HK)9月7日耗資約113.9萬港元回購5.35萬股

榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

康寧傑瑞製藥-B(09966)9月7日斥資98.92萬港元回購11.5萬股

康寧傑瑞製藥-B(09966.HK)9月7日斥資98.92萬港元回購11.5萬股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=12"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.91403,"timestamp":1789624610032,"preClose":482.35672,"halted":0,"volume":40009211,"delay":0,"changeRate":0.003229,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":1.557312,"latestTime":"09-17 13:56:57","open":482.07187,"high":489.93134,"low":481.40475,"amount":912324743,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789632600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.001522,"increases":17,"decrements":9,"flats":6,"marketCap":307526329232,"floatMarketCap":273408248808},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":483.91403,"volume":40009211,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.001522,"peRate":160.310337,"marketCap":307526329232,"floatMarketCap":273408248808,"timestamp":1789624610032,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":9,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:12,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665932548","title":"「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:43","pubTimestamp":1788856994,"startTime":"0","endTime":"0","summary":"9月7日盘前，开拓药业-B发布公告，宣布其自主研发的抑制黑色素生成的新型高效酪氨酸酶抑制剂KT-939的人体长期安全性试验已于2026年9月4日顺利结束。初步数据显示，合计114位受试者连续52周使用KT-939后，未出现皮肤不良反应，且与该试验中期28周临床使用结果一致，充分展现了KT-939具有良好的安全性。在该利好消息刺激下，开拓药业股价当日开盘后迅速走高，半小时内涨幅拉升至9.89%，股价再次站上2港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665853325","title":"康方生物(09926)出現大手賣出23.3萬股，成交價$96.2，涉資2.241千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2665853325","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665853325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:08","pubTimestamp":1788854880,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在下午04:08出现大手卖出，成交量为23.3万，成交价为港币$96.2，涉资2.241千万。至目前为止，股价升0.208%，今日最高价为$97.3，而最低价为$94.75，总成交量为574.038万股，总成交金额港币$5.509亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609086589/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609086589/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0417516571.SGD","LU0348766576.USD","LU2488822045.USD","LU0348825331.USD","BK1161","LU2399975544.HKD","LU1720050803.USD","LU0348783233.USD","LU0634319403.HKD","LU0417516902.SGD","KURE","LU0417516738.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348827113.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1961090484.USD","09926","LU2476274308.USD","LU0540923850.HKD","LU2476274720.SGD","LU0561508036.HKD","LU0348767384.USD","IE00B543WZ88.USD","LU0348784397.USD","LU2778985437.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665328507","title":"南新制藥信披違規收處罰，受損股民可索賠","url":"https://stock-news.laohu8.com/highlight/detail?id=2665328507","media":"市场资讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665328507?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 15:16","pubTimestamp":1788851760,"startTime":"0","endTime":"0","summary":"调查显示，公司在收入确认和利润核算方面存在不规范情形，最终造成2023年年报披露的营业收入和利润总额被高估。具体来看，一部分客户发生退货后，公司没有按照规定及时冲减相关收入及利润，由此多计营业收入4435.88万元，多计利润总额908.77万元。两项合计，2023年营业收入被虚增6468.28万元，占当年披露营业收入的8.69%；利润总额被虚增1195.22万元，占当期披露利润总额的157.11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-09-08/doc-inirayqy4696989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665347954","title":"英硅智能（03696）揚升9.32% 機構看好其在AI製藥領域價值持續兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665347954","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665347954?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:10","pubTimestamp":1788847816,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英硅智能 午后涨幅进一步扩大，一度涨逾12%，截至发稿，最新报52.10港元，涨幅9.32%，成交额10.03亿港元。同时基于公司长期积累的数据、基准测试和研发经验积极拓展MMAI Gym对外合作，该机构表示看好公司在AI制药领域价值持续兑现。预计英硅智能2026-2028年营收分别为169.92、235.99、305.59百万美元，同比增长202.14%、38.88%以及29.49%，净利润分别为29.96、71.06、117.13百万美元，同比增长108.50%、137.18%以及64.85%，维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991015","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1141","BK1191","VTHR","AGIX","AIPO","QTOC","CHAT","ARTY","BK1574","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934210","title":"港股異動 | 百奧賽圖-B(02315)午後升逾10% 與齊魯製藥簽署全人納米抗體分子非排他授權合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934210","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665934210?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:53","pubTimestamp":1788846789,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano纳米抗体平台产生。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","BK1161","01477","BK4588","BK1191","KCAI","688796","VXUS","BK0216","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665996342","title":"港股異動 | CRO概念股震盪走高 企業在手訂單呈「量價齊升」 AI製藥有望重塑醫藥研發業態","url":"https://stock-news.laohu8.com/highlight/detail?id=2665996342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665996342?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:43","pubTimestamp":1788846222,"startTime":"0","endTime":"0","summary":"分析指出，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。招商证券研报指出，CXO板块景气度明确上行。今年上半年国内CXO板块营收、归母净利润同比分别增长24.5%、52.7%，利润增速接近上一轮周期高点；在手订单与新签订单全面回暖，龙头上调全年指引。此外，AI制药有望重塑医药研发业态，提升药物研发效率，板块亦将受益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","JHMH","03347","06821","AIPO","BK1574","BK1583","HK0000306701.USD","QTOC","VXUS","BK4585","BME","01477","BK1576","BK1141","HK0000306685.HKD","01548","KCAI","ARTY","LRND","CHAT","03759","VTHR","BK4588","HK0000320264.USD","HK0000320223.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665426603","title":"港股異動 | 基石藥業-B(02616)午後升逾6% 獲納入港股通標的證券名單 國際大行相繼看好公司發展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2665426603","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665426603?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:41","pubTimestamp":1788846117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。其中，高盛预计，未来6至12个月将是基石药业关键催化剂密集兑现的阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02616","VXUS","BK1161","FLHK","BK1574","KCAI","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113703587","title":"港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113703587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113703587?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:33","pubTimestamp":1788845625,"startTime":"0","endTime":"0","summary":"9月8日，港股$生物(000504)$医药股午后走强，$剂泰科技-P(07666)$涨近15%，$百奥赛图-B(02315)$、$金斯瑞生物科技(01548)$涨近10%，$泰格医药(03347)$、$康希诺生物(06185)$、$云顶新耀(01952)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","VXUS","XBI","BK1161","161726","BK1583","BK1141","HK0000306701.USD","BK1515","07666","01952","06185","399441","HK0000306685.HKD","688796","BK4581","HK0000320223.HKD","BK0216","01548","HK0000320264.USD","BK1576","09939","BK1191","KCAI","03347","BK4588","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665412573","title":"港股異動 | 雲頂新耀(01952.HK)早盤升逾5% 星必妥PSVT適應症新藥上市申請在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2665412573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665412573?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:53","pubTimestamp":1788839607,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341252","title":"港股異動 | 雲頂新耀(01952)早盤升逾5% 星必妥PSVT適應症新藥上市申請在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341252","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:53","pubTimestamp":1788839607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀(01952)早盘涨超5%。截至发稿，涨4.73%，报32.78港元，成交额1.51亿港元。消息面上，9月3日，云顶新耀宣布，国家药品监督管理局(NMPA)已批准星必妥®(艾曲帕米鼻喷雾剂)的新药上市许可申请(NDA)，用于治疗成人阵发性室上性心动过速(PSVT)急性症状发作，转复为窦性心律。星必妥已于2025年12月获得美国食品药品监督管理局(FDA)批准，成为30余年来首款且唯一获批用于成人PSVT急性症状发作治疗的创新疗法。此次在中国获批，意味着这一创新疗法正式进入中国市场，成为云顶新耀在心血管疾病领域首个获批产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1583","KCAI","BK1161","BK1574","BK4588","BK4585","01952","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341826","title":"酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341826","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:13","pubTimestamp":1788837196,"startTime":"0","endTime":"0","summary":"算上诺华，已有10家全球制药巨头为ALT-B4签下许可协议。有意思的地方在于：这些交易里没有一款新药。2025年9月，默沙东的Keytruda Qlex获FDA批准，成为首个使用ALT-B4的商业化产品。第一张牌，宝济药业的“国产first”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788753577275365008","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","159992","MEDX","IBBQ","BK1161","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665434161","title":"中信建投：醫療器械業績持續改善 醫療服務收入平穩增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2665434161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665434161?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:56","pubTimestamp":1788836160,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。IVD：26Q2 IVD板块收入在过去两年来首次恢复正增长，利润端大幅增长。从收入端来看，二季度板块收入仍保持正增长，其中眼科医疗服务公司2025Q2低基数相对较低，但板块今年二季度收入增速相较一季度的增速有所降低，表明消费环境压力仍然存在。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","BK1574","09996","MDEV","MEDX","159883","LGHT","HART","AGNG","LNGR","PTH","RSPH","GDOC","IEIH","BK1583","BK1100","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349337","title":"港股異動 | 禮邦醫藥-B(09637.HK)升逾6% 納入港股通及恒生綜合指數落地 美信羅銷售按年增約105% 商業化兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349337?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","BK1161","BK1574","09939","HSCI","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665334349","title":"港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地 美信羅銷售按年增約105% 商業化兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334349","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":"深交所9月7日公告亦确认09637调入港股通标的证券名单。礼邦医药于8月26日披露上市后首份中期业绩，2026年上半年收入人民币1.042亿元，同比增长761.2%，主要来自美信罗销售及AP306许可收入，期内亏损人民币1.626亿元，同比收窄22.5%。其中，商业化产品美信罗实现销售收入人民币2480万元，同比增长约105%，覆盖医院超300家，毛利率由2025年上半年的43.4%升至47.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","VXUS","159938","09637","BK1515","FLHK","HSCI","BK4588","BK1191","09939","KCAI","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312996","title":"大瓜！券商醫藥研究員轉行看電子去了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312996","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665312996?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 21:05","pubTimestamp":1788786300,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！（来源：花尔街之狼）券商医药研究员转行看电子去了本科硕士都学的医学，怎么转行看电子了？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-07/doc-iniqzhfu5386610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1161","159938","BK1574","BK1515","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311078","title":"上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311078","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311078?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:39","pubTimestamp":1788784781,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段，走向“赚钱才是硬道理”的价值兑现期。这种转变并非行业普遍现象，而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866904351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866904351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","KURE","BK1588","BK4139","ONC","688235","MEDX","LU1303224171.USD","LU1969619763.USD","LU1719994722.HKD","LU0828237510.HKD","BK4526","BK1583","LU0588546209.SGD","159992","LU0307460666.USD","BK1161","LU1770034418.SGD","BK4588","LU1251922891.USD","BK0239","IBBQ","BK1574","BK4585","06160","LNGR","LU0228659784.USD","LU2328871848.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831152","title":"歸創通橋(02190.HK)9月7日耗資約113.9萬港元回購5.35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831152?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:13","pubTimestamp":1788783192,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1587","BK1583","BK1574","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665731933?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09995","LU2328871848.SGD","BK1583","LU2148510915.USD","LU1969619763.USD","IBBQ","LNGR","MEDX","BK0239","06978","LU1064130708.USD","LU2488822045.USD","BK1574","BK1161","688331","159992","KSTR","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665441315","title":"康寧傑瑞製藥-B(09966)9月7日斥資98.92萬港元回購11.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665441315","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665441315?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:17","pubTimestamp":1788776264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月7日斥资98.92万港元回购11.5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B(09966)9月7日斥资98.92万港元回购11.5万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315426","title":"康寧傑瑞製藥-B(09966.HK)9月7日斥資98.92萬港元回購11.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315426?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:17","pubTimestamp":1788776264,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":12,"totalSize":330,"code":"91000000","status":"200"}]}}